Business Insider

Angion Initiates Dosing in Phase 1 Clinical Trial Evaluating ANG-3070, a Dual-Kinase Inhibitor for the Treatment of Fibrotic Diseases

SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing first-in-class therapies to treat acute kidney injury and other ...
Business Wire

Angion Biomedica Enters Multi-Institutional Alliance to Advance Novel and Promising Therapies for Ischemic Stroke

GARDEN CITY, N.Y.--(BUSINESS WIRE)--Angion Biomedica Corp. announced today the establishment of an alliance with Duke University and Massachusetts General Hospital (MGH) to pursue advanced development ...
Business Wire

Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the ...
Seeking Alpha

Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split

NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small ...
Nasdaq

Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021

ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases ...
Nasdaq

Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function

UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not ...